IDXX stock forecast, quote, news & analysis
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock... Show more
IDEXX Laboratories (IDXX) Stock Analysis: Recurring Diagnostics Growth Meets a Premium Valuation Ahead of Earnings
Key Takeaways
- IDEXX Laboratories (IDXX) closed at $551.21 on October 30, 2026, up roughly 5.6% from $522.19 a month earlier — a moderate advance that keeps the stock in rangebound territory rather than a sharp breakout.
- The shares fell 4.3% in the final session of the period, on elevated volume, as investors positioned ahead of the company's third-quarter 2026 results.
- Companion Animal Group (CAG) Diagnostics recurring revenue grew about 10.3% organically in the second quarter of 2026, supporting an upwardly revised full-year outlook.
- The company's September acquisition of CoVetAI added AI-native veterinary workflow software, extending IDEXX's connected diagnostics and software ecosystem.
- Wall Street consensus on IDXX remains a "Buy," with an average price target near $694, though a premium forward earnings multiple leaves limited room for execution missteps.
- Softer U.S. veterinary clinical and wellness visits continue to be the primary demand watch item for investors.
- For additional detail on valuation and fundamentals, explore IDEXX's Price Targets, Earnings, and Forecast pages.
- For automated trading ideas across thousands of tickers, explore Trending AI Robots.
Current Market Snapshot
IDEXX Laboratories shares have traded in a relatively narrow band over the past month. After dipping toward the low $500s in mid-September, the stock recovered through October and reached a multi-month high of $575.98 on October 29, 2026, before pulling back 4.3% to close at $551.21 on October 30. Measured against the $522.19 close on September 30, the stock advanced approximately 5.6% over the trailing 30 days. On a longer view, the shares have been essentially flat over the past quarter, oscillating between roughly $500 and $576 as investors weigh durable recurring diagnostics growth against a valuation that remains well above broader market benchmarks.
IDEXX Laboratories (IDXX) Business Overview and Competitive Position
IDEXX Laboratories is a global leader in pet healthcare innovation and veterinary diagnostics. Headquartered in Westbrook, Maine, and a member of the S&P 500, the company serves customers in more than 175 countries. Its Companion Animal Group (CAG) accounts for the large majority of revenue and includes reference laboratory services, in-clinic instruments and consumables (such as the Catalyst and inVue Dx platforms), rapid assays, and veterinary software and diagnostic imaging. The company also operates Water and Livestock, Poultry and Dairy (LPD) testing segments.
IDEXX's competitive strength rests on a sticky, recurring-revenue model: a growing installed base of diagnostic instruments drives repeat consumable and test purchases, while proprietary software and reference lab relationships deepen customer retention. Investors follow the stock closely because the company's diagnostics franchise generates predictable, high-margin cash flows tied to long-term trends in pet ownership and animal healthcare spending.
Recent Developments Driving IDXX
Several verified developments shaped sentiment over the last 30 days. In mid-September, IDEXX completed the acquisition of CoVetAI, an AI-native veterinary workflow company, strengthening its software and clinical decision-support capabilities. The company also expanded its Faecal Dx antigen testing platform in the United Kingdom with taeniid tapeworm detection, broadening its recurring testing menu.
On the analyst front, Goldman Sachs initiated coverage with a Buy rating and a $740 price target in mid-October, while J.P. Morgan reiterated a Buy and raised its target to $750. UBS reiterated a Hold rating with a reduced $627 target. Overall, consensus remains constructive, with an average price target near $694. The stock's late-October decline occurred ahead of the company's third-quarter results, which were scheduled for November 2, 2026, with analysts modeling earnings of about $3.71 per share on revenue near $1.19 billion — implying mid-to-high single-digit growth from the prior-year period.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots from a broader universe of hundreds of bots that trade thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving traders a streamlined view of strategies that are currently standing out. The bots vary widely in approach, trading timeframe, and performance metrics, allowing users to evaluate options that align with different risk tolerances and objectives. For investors seeking systematic, data-driven signals across a wide range of stocks, the page offers a practical starting point for further exploration.
2026 Outlook and What Investors Should Watch
Looking ahead, IDEXX's trajectory hinges on several measurable drivers. The company's inVue Dx instrument placements — which surpassed 9,000 units in the installed base during the second quarter — and the ongoing expansion of Cancer Dx testing into mast cell tumor detection represent key recurring-revenue growth engines. Management's full-year guidance implies double-digit comparable earnings growth, supported by roughly 4% net price realization and steady volume gains.
The principal risks to monitor are demand-related. U.S. same-store clinical visits declined an estimated 1.3% in the second quarter of 2026, with wellness visits showing greater weakness, and management has assumed continued softness into the second half of the year. Foreign exchange movements and a premium forward price-to-earnings ratio near 34 also remain factors that could influence both fundamentals and valuation. Investors should watch quarterly guidance updates, clinical visit trends, international expansion progress, and further integration of the CoVetAI acquisition as signals of whether the company can sustain its growth trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IDXX in upward trend: 10-day moving average moved above 50-day moving average on October 21, 2026
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on IDXX as a result. In 55 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 177 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.812) is normal, around the industry mean (65.876). P/E Ratio (46.935) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties